<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0872-8178</journal-id>
<journal-title><![CDATA[Jornal Português de Gastrenterologia ]]></journal-title>
<abbrev-journal-title><![CDATA[J Port Gastrenterol.]]></abbrev-journal-title>
<issn>0872-8178</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Gastrenterologia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0872-81782006000200002</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Eficácia e segurança do infliximab no tratamento da doença de crohn: experiência de um centro português]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sousa]]></surname>
<given-names><![CDATA[H. T.]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Portela]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Leitão]]></surname>
<given-names><![CDATA[M. C.]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Freitas]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</contrib>
</contrib-group>
<aff id="A">
<institution><![CDATA[,  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2006</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2006</year>
</pub-date>
<volume>13</volume>
<numero>2</numero>
<fpage>75</fpage>
<lpage>81</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S0872-81782006000200002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S0872-81782006000200002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S0872-81782006000200002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Objectivos: Avaliação da eficácia e segurança da terapêutica com infliximab efectuada no nosso serviço em doentes portadores de DC. Material e Métodos: Revisão dos processos dos doentes com DC seguidos no nosso serviço, submetidos a pelo menos uma infusão de infliximab até 2004. Resultados: Foram tratados 54 (18,7%) doentes com DC. Estudaram-se 52, cuja DC tinha 8,5 (1-28) anos de evolução. As indicações foram doença luminal activa em 24 (46,2%) doentes, fístulas activas em 22 (42,3%) e ambas em 6 (11,5%). Efectuaram-se 226 infusões, com 4,3 (1-24) infusões por doente. Aindução seguiu o protocolo triplo em 38 (73,1%) doentes. No início do tratamento 84,6% dos doentes estavam sob imunossupressão. Registaram-se efeitos adversos em 19 (36,5%) doentes, que foram graves em 9 (17,3%). Cerca de 2/3 dos doentes responderam à indução e 3/4 dos doentes em manutenção mantêm resposta positiva. No final do follow-up, 28 (53,0%) doentes mantinham resposta favorável, estando 13 (25,0%) em remissão completa. Conclusões: Metade dos doentes infundidos melhorou clinicamente de modo estável, metade dos quais em remissão completa. Ocorreram efeitos adversos em cerca de 1/3 dos doentes, implicando a descontinuação da droga em menos de 10%.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Aims: Evaluation of efficacy and safety of infliximab treatment in Crohn's disease (CD), performed at our department. Methods: Medical records of patients with CD followed at our department and treated with infliximab until 2004 were reviewed. Results: Fifty-four (18,7%) patients with CD were treated with infliximab. Fifty-two patients were studied, with a 8,5 (1-28) year DC on average. Indications for treatment were inflammatory luminal disease in 24 (46,2%) patients, active fistulas in 22 (42,3%) and both in 6 (11,5%). Each patient received 4,3 (1-24) infusions, on average, for a total of 226 infusions. On starting infliximab, 84,6% of patients were also on imunossupressive treatment. Adverse events occurred in 19 (36,5%), being serious in 9 (17,3%). In about 2/3 of patients responded to the induction scheme and 3/4 of patients on maintenance uphold a positive response. At the end of follow-up, 28 (53,0%) patients sustained a positive response, with 13 (25,0%) in complete remission. Conclusions: Half of the patients clinically and steadily improved, with half of these in complete remission. Adverse events occurred in about 1/3 of patients, which warranted discontinuation of treatment in less than 10%.]]></p></abstract>
</article-meta>
</front><body><![CDATA[  ]]></body><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanauer]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Feagan]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
<name>
<surname><![CDATA[Lichtenstein]]></surname>
<given-names><![CDATA[G R]]></given-names>
</name>
<name>
<surname><![CDATA[Mayer]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Schreiber]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Colombel]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2002</year>
<numero>359</numero>
<issue>359</issue>
<page-range>1541-1549</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
